Opens 1 December. Book a demo.

18 Nov 2026 · UK · Facebook · News

ASA rules against five Voy low testosterone ads

On 18 November 2026 the ASA ruled against Voy's low testosterone posters and Facebook ads for overstating symptom links and a prevalence claim.

What happened

On 18 November 2026 the ASA published a ruling on Menwell Ltd, trading as Voy, an online healthcare provider. It covered four posters and two paid Facebook ads seen in January 2026 that tied symptoms such as irritability, fatigue and anxiety to low testosterone and promoted an at-home test. The ASA upheld all three issues it investigated. It found that three of the posters and one Facebook ad exaggerated the likely link between common symptoms and low testosterone, and that the Facebook ad also presented low testosterone as the explanation without conditional language. It also found that the claim that low testosterone affects one in four men over 30 was not substantiated, because the study behind it only counted men who already showed symptoms, and only 5.6% met the criteria for symptomatic deficiency.

What it means for your content

This week, check any post that pairs an everyday symptom with a named condition, such as tiredness with a hormone problem. The ASA accepted conditional wording like “might”, but it still ruled against ads that overstated how strongly a symptom points to the condition. If you quote a prevalence figure, check who was in the study and whether the number matches what your post implies. Personal stories that present a condition as the cause of someone’s struggles are a risk too, so keep them open to other explanations.

See how we set up a regulatory check for your market

Source

Author

Taras Kopytko, Founder, PackCraft

Published 18 Nov 2026

We turn changes like this into your monthly content plan. You approve every piece.

Book a demoMore from Insights